Brief: Belite Bio Finalizes Phase 3 Clinical Trial Plans For Advanced Dry AMD Treatment With Tinlarebant (LBS-008)
18/11/2022 13:14
Nov 18 (Reuters) - Belite Bio Inc BLTE.O :
* BELITE BIO FINALIZES PHASE 3 CLINICAL TRIAL PLANS FOR
ADVANCED
DRY AMD TREATMENT WITH TINLAREBANT (LBS-008)
* BELITE BIO - TINLAREBANT GRANTED FAST TRACK DESIGNATION,
RARE
PEDIATRIC DISEASE DESIGNATION IN U.S., ORPHAN DRUG DESIGNATION
IN U.S., EUROPE FOR STGD1
* BELITE BIO INC - 12-MONTH INTERIM DATA FROM ONGOING PHASE
2
STGD1 STUDY CONTINUES TO SHOW HALTING OR SLOWING OF LESION
GROWTH
* BELITE BIO INC - GLOBAL PHASE 3 STUDY IN ADOLESCENT STGD1
PATIENTS ( "DRAGON" STUDY) IS RECRUITING SUBJECTS
* BELITE BIO INC - A 2-YEAR PHASE 2 STUDY IN ADOLESCENT
STGD1
PATIENTS IS ONGOING
Source text for Eikon: ID:nGNX2dK5Qd
Further company coverage: BLTE.O
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses